Gilead Sciences (GILD)
(Delayed Data from NSDQ)
$73.78 USD
-0.56 (-0.75%)
Updated Aug 16, 2024 04:00 PM ET
After-Market: $73.77 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth B Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$73.78 USD
-0.56 (-0.75%)
Updated Aug 16, 2024 04:00 PM ET
After-Market: $73.77 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth B Momentum A VGM
Zacks News
Novartis to Donate Generic Hydroxychloroquine for Coronavirus
by Zacks Equity Research
Novartis (NVS) will donate 130 million doses of generic hydroxychloroquine for COVID-19 treatment.
Gilead's HCV Drug Epclusa Gets FDA Nod for Expanded Age Group
by Zacks Equity Research
The FDA approves Gilead's (GILD) sNDA for Epclusa to treat chronic hepatitis C infection in children aged six years and above or weighing at least 17 kg.
Mylan, Teva in Focus As Chloroquine Being Tested for Coronavirus
by Ekta Bagri
Malaria drug, chloroquine, is being tested for the treatment of patients infected with COVID-19. Generic makers, Mylan and Teva ramp up efforts to contribute to the same.
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed at $78.55 in the latest trading session, marking a -1.1% move from the prior day.
Drugs or Vaccines: Which Will Be More Crucial Against Coronavirus?
by Ekta Bagri
Given the urgent need for curing infected COVID-19 patients, we take a look at companies developing drugs/treatments for the same.
The Zacks Analyst Blog Highlights: REGN, SNY, GILD and MRNA
by Zacks Equity Research
The Zacks Analyst Blog Highlights: REGN, SNY, GILD and MRNA
Pfizer, Regeneron Give Update on Coronavirus Drug Development
by Kinjel Shah
Pfizer (PFE) to jointly develop BioNTech's potential coronavirus vaccine. Regeneron (REGN) could start clinical studies of a COVID-19 therapy by this summer.
Regeneron Up on Identification of Antibodies for Coronavirus
by Zacks Equity Research
Regeneron (REGN) announces identification of antibodies from its VelocImmune mice for the treatment of coronavirus.
Mallinckrodt Completes NDA Submission for Kidney Failure Drug
by Zacks Equity Research
Mallinckrodt (MNK) nears approval of its kidney failure candidate, terlipressin, with the completion of rolling submission of an NDA for the same.
These 10 Drug Companies are Testing a Coronavirus Vaccine
by Madeleine Johnson
As the coronavirus pandemic continues to spread, some of the biggest drug companies are moving closer to finding a vaccine.
Regeneron/Sanofi to Test Kevzara for Severe Coronavirus Infection
by Kinjel Shah
A U.S. based phase II/III study has been initiated to evaluate Regeneron (REGN)/Sanofi's (SNY) rheumatoid arthritis drug Kevzara to treat patients with severe COVID-19.
Moderna Up as First Human Trial of Coronavirus Vaccine Begins
by Zacks Equity Research
Moderna (MRNA) announces dosing of first human in a phase I clinical study evaluating its coronavirus vaccine candidate. The National Institutes of Health is conducting the study.
Gilead Up as Remdesivir Shows Promise in Treating Coronavirus
by Zacks Equity Research
Gilead (GILD) leads the race of companies developing treatments for coronavirus with experimental candidate, remdesivir, showing promise.
4 Big Drug/Biotech Stocks Up in Coronavirus-Hit Economy
by Kinjel Shah
Here we highlight four bigshot drugmakers/biotechs whose stocks are up this year in spite of the coronavirus impact.
J&J Signs Another Collaboration to Develop Coronavirus Vaccine
by Zacks Equity Research
J&J (JNJ) is actively pursuing its development plans related to coronavirus vaccine. The company is partnering with several public/private organizations to accelerate its vaccine development.
The Zacks Analyst Blog Highlights: HENKY, NFLX, PTON, TDOC and GILD
by Zacks Equity Research
The Zacks Analyst Blog Highlights: HENKY, NFLX, PTON, TDOC and GILD
Agenus (AGEN) Q4 Earnings Beat Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Agenus (AGEN) betters loss estimates and also beats on sales in the fourth quarter. The company gets a Fast Track tag for balstilimab & zalifrelimab combo to address the second-line cervical cancer.
Coronavirus Drug Development Efforts Pick Up Amid Sell-Off
by Kinjel Shah
Several drug/biotech companies are working on making new antibodies, drugs and vaccines to prevent and treat COVID-19.
Roche's (RHHBY) Coronavirus Test Achieves EUA From the FDA
by Zacks Equity Research
Roche's (RHHBY) cobas SARS-CoV-2 Test for the qualitative detection of SARS-CoV-2, the virus that causes the COVID-19 disease, gets EUA from the FDA.
Biotech Sector in Focus as Coronavirus Spreads Panic
by Ekta Bagri
The outbreak of COVID-19 has brought the volatile biotech sector under the spotlight as both large and small companies rush to develop treatments and vaccines to combat this pandemic.
4 Sectors in Focus Following Coronavirus-Induced Selloff
by Urmimala Biswas
While COVID-19 has dealt a huge blow to most sectors, it has opened up enormous opportunities for a few.
3 Small Biotechs Provide Coronavirus Drug Development Updates
by Kinjel Shah
Several drug/biotech companies are working on making new antibodies, drugs, and vaccines to prevent and treat COVID-19.
New Strong Sell Stocks for March 12th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
Gilead (GILD) Announces Positive Long-Term Results on Descovy
by Zacks Equity Research
Gilead (GILD) announces long-term results from the DISCOVER study, which showed that Descovy is effective for HIV prevention with non-inferior efficacy to Truvada.
Biotech Stock Roundup: NVAX, CANF Up on Coronavirus Treatment Updates & More
by Zacks Equity Research
The biotech sector is in focus with pipeline updates from companies evaluating treatments for the novel COVID-19.